I. Meineke

发表

Genetic Variation in the Renal Sodium Transporters NKCC2, NCC, and ENaC in Relation to the Effects of Loop Diuretic Drugs

J. Brockmöller, P. Nürnberg, M. Toliat, 2007, Clinical pharmacology and therapeutics.

Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans.

C. Meisel, J. Brockmöller, I. Roots, 2003, British journal of clinical pharmacology.

Population pharmacokinetics of sevoflurane in conjunction with the AnaConDa®: toward target‐controlled infusion of volatiles into the breathing system

T. Bouillon, I. Meineke, M. Enlund, 2008, Acta anaesthesiologica Scandinavica.

Oxygen 93: a new option for European hospitals.

J. Rathgeber, I. Meineke, K. Zuechner, 2014, British journal of anaesthesia.

Increased psychological responses and divergent neuroendocrine responses to m‐CPP and ipsapirone in patients with panic disorder

E. Rüther, G. Hajak, A. Broocks, 2000, International clinical psychopharmacology.

Dominant contribution of P450 3A4 to the hepatic carcinogenic activation of aflatoxin B1.

J. Brockmöller, L. Wojnowski, I. Meineke, 2006, Chemical research in toxicology.

CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide

J. Brockmöller, S. Vormfelde, I. Meineke, 2004, Clinical pharmacology and therapeutics.

Effects of Polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on Trimipramine Pharmacokinetics

K. Wernecke, J. Brockmöller, I. Roots, 2003, Journal of clinical psychopharmacology.

Trimipramine pharmacokinetics after intravenous and oral administration in carriers of CYP2D6 genotypes predicting poor, extensive and ultrahigh activity.

J. Sasse, J. Brockmöller, I. Roots, 2003, Pharmacogenetics.

Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers.

J. Brockmöller, I. Roots, I. Meineke, 2002, Pharmacogenetics.

Population pharmacokinetic analysis of meloxicam in rheumatoid arthritis patients.

I. Meineke, D. Türck, 2003, British journal of clinical pharmacology.

Effects of OCT1 polymorphisms on the cellular uptake, plasma concentrations and efficacy of the 5-HT3 antagonists tropisetron and ondansetron

R. Kaiser, J. Brockmöller, M. Tzvetkov, 2010, The Pharmacogenomics Journal.

The Polymorphisms Asn130Asp and Val174Ala in OATP1B1 and the CYP2C9 Allele *3 Independently Affect Torsemide Pharmacokinetics and Pharmacodynamics

J. Brockmöller, P. Nürnberg, M. Toliat, 2008, Clinical pharmacology and therapeutics.

Population Pharmacokinetics of Melphalan and Glutathione S‐transferase Polymorphisms in Relation to Side Effects

R. Kaiser, J. Brockmöller, L. Trümper, 2008, Clinical pharmacology and therapeutics.

Carbonyl Reductase 1 Is a Predominant Doxorubicin Reductase in the Human Liver

K. Huse, J. Brockmöller, L. Wojnowski, 2008, Drug Metabolism and Disposition.

Interindividual Variation in the Pharmacokinetics of Δ9‐Tetrahydrocannabinol as Related to Genetic Polymorphisms in CYP2C9

J. Brockmöller, D. Sehrt, I. Meineke, 2009, Clinical pharmacology and therapeutics.

Genetic variation at the CYP2C locus and its association with torsemide biotransformation

J. Brockmöller, P. Nürnberg, M. Toliat, 2007, The Pharmacogenomics Journal.

Pharmacokinetic modelling of morphine, morphine-3-glucuronide and morphine-6-glucuronide in plasma and cerebrospinal fluid of neurosurgical patients after short-term infusion of morphine.

U. Hofmann, J. Brockmöller, M. Schwab, 2002, British journal of clinical pharmacology.

Pantoprazole lacks interaction with antipyrine in man, either by inhibition or induction.

I. Meineke, W. Wurst, V. Steinijans, 1994, International journal of clinical pharmacology and therapeutics.

Sensitive high-performance liquid chromatographic determination of pseudoephedrine in plasma and urine.

E. Brendel, I. Meineke, C. D. De Mey, 1988, Journal of chromatography.

Pharmacokinetics of doxepin and desmethyldoxepin: an evaluation with the population approach

I. Meineke, C. Gleiter, K. Schreeb, 2002, European Journal of Clinical Pharmacology.

Pharmacokinetic Characterization of Amantadine in Human Brain Tissue

J. Kornhuber, J. Wiltfang, P. Riederer, 2006, Therapeutic drug monitoring.

Postprandial changes in supine and erect heart rate, systemic blood pressure and plasma noradrenaline and renin activity in normal subjects

E. Brendel, I. Meineke, C. Mey, 2004, European Journal of Clinical Pharmacology.

Cardiovascular effects of eating, atenolol and their interaction: beta1-adrenergic modulation does not play a predominant role in the genesis of postprandial effects.

I. Meineke, C. D. De Mey, D. Enterling, 1993, British journal of clinical pharmacology.

Cardiovascular effects ofeating, atenolol andtheir interaction: P-adrenergic modulation doesnotplay apredominant role in thegenesis ofpostprandial effects

I. Meineke, C. Mey, D. Enterling, 1993 .

Time course and nature of postprandial haemodynamic changes in normal man.

I. Meineke, C. D. De Mey, D. Enterling, 1989, Clinical physiology.

Impact of genetic polymorphisms in CYP2C8 and rosiglitazone intake on the urinary excretion of dihydroxyeicosatrienoic acids.

U. Fuhr, J. Brockmöller, C. Rodríguez-Antona, 2008, Pharmacogenomics.

Impact of the CYP2D6 ultra-rapid metabolizer genotype on doxepin pharmacokinetics and serotonin in platelets

J. Brockmöller, M. Tzvetkov, I. Roots, 2005, Pharmacogenetics and genomics.

Routine measurement of plasma catecholamines in clinical pharmacology by high-performance liquid chromatography with electrochemical detection.

E. Brendel, I. Meineke, C. D. De Mey, 1989, Journal of chromatography.

Persistence of haloperidol in human brain tissue.

J. Kornhuber, J. Wiltfang, P. Riederer, 1999, The American journal of psychiatry.

Treatment of Helicobacter pylori-Positive Lesions: 13C-Urea Breath Test Monitoring and Morphology

A. Schauer, I. Meineke, F. Lüdtke, 1993 .

Therapeutic Drug Monitoring of Mirtazapine, Desmethylmirtazapine, 8-Hydroxymirtazapine, and Mirtazapine-N-oxide by Enantioselective HPLC With Fluorescence Detection

J. Brockmöller, I. Meineke, J. Kirchheiner, 2006, Therapeutic drug monitoring.

Therapeutic Drug Monitoring of Mirtazapine and Its Metabolite Desmethylmirtazapine by HPLC with Fluorescence Detection

E. Rüther, J. Brockmöller, I. Meineke, 2004, Therapeutic drug monitoring.

Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6.

J. Sasse, J. Brockmöller, I. Roots, 2003, Pharmacogenetics.

Relative potency of proton-pump inhibitors—comparison of effects on intragastric pH

U. Fuhr, U. Klotz, J. Brockmöller, 2008, European Journal of Clinical Pharmacology.

Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6.

J. Sasse, J. Brockmöller, I. Roots, 2003, Pharmacogenetics.

Impact of the CYP2D6 Ultrarapid Metabolizer Genotype on Mirtazapine Pharmacokinetics and Adverse Events in Healthy Volunteers

J. Brockmöller, I. Roots, I. Meineke, 2004, Journal of clinical psychopharmacology.

Pharmacokinetics of Mirtazapine: Enantioselective Effects of the CYP2D6 Ultra Rapid Metabolizer Genotype and Correlation with Adverse Effects

J. Brockmöller, I. Meineke, J. Kirchheiner, 2007, Clinical pharmacology and therapeutics.

Non-response to maprotiline caused by ultra-rapid metabolism that is different from CYP2D6?

U. Gundert-Remy, S. Vormfelde, I. Meineke, 1997, European Journal of Clinical Pharmacology.

Determination of 2-hydroxyphenylacetic acid (2HPAA) in urine after oral and parenteral administration of coumarin by gas-liquid chromatography with flame-ionization detection.

U. Gundert-Remy, I. Meineke, R. Kahl, 1998, Journal of pharmaceutical and biomedical analysis.

High-performance liquid chromatographic determination of cefonicid in human plasma and urine.

E. Brendel, I. Meineke, M. Zschunke, 1985, Journal of chromatography.

Influence of urine pH and urinary flow on the renal excretion of memantine.

I Meineke, U. Gundert-Remy, I. Meineke, 1998, British journal of clinical pharmacology.

Memantine Pharmacotherapy

J. Kornhuber, J. Wiltfang, S. Bleich, 2007, Clinical pharmacokinetics.

Assessment of Drug Accumulation in the Evaluation of Pharmacokinetic Data

I. Meineke, C. Gleiter, 1998, Journal of clinical pharmacology.

Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics.

J. Brockmöller, M. Tzvetkov, D. Sehrt, 2011, Pharmacogenomics.

The Effects of Genetic Polymorphisms in the Organic Cation Transporters OCT1, OCT2, and OCT3 on the Renal Clearance of Metformin

I Meineke, J. Brockmöller, H. Koepsell, 2009, Clinical pharmacology and therapeutics.

Region specific distribution of levomepromazine in the human brain

J. Kornhuber, J. Wiltfang, P. Riederer, 2006, Journal of Neural Transmission.

Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers.

C. Meisel, J. Brockmöller, W. Rohde, 2002, Pharmacogenetics.

Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2

C. Meisel, J. Brockmöller, I. Roots, 2002, Clinical pharmacology and therapeutics.

Population pharmacokinetics of piritramide in surgical patients.

A. Hoeft, T. Bouillon, R. Port, 1999, Anesthesiology.

Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration.

J. Brockmöller, J. Stingl, M. Tzvetkov, 2013, Biochemical pharmacology.

Assay of antipyrine and its main metabolites 3-hydroxymethylantipyrine, norantipyrine and 4-hydroxyantipyrine in urine.

E. Brendel, I. Meineke, C. D. De Mey, 1989, Journal of pharmaceutical and biomedical analysis.

Interactions between domperidone and ropinirole, a novel dopamine D2-receptor agonist.

I. Meineke, C. D. De Mey, D. Enterling, 1991, British journal of clinical pharmacology.

Stability of 5-aminosalicylic acid and 5-acetylaminosalicylic acid in plasma.

E. Brendel, I. Meineke, E. Stüwe, 1988, Journal of chromatography.

Amelogenin-based sex identification as a strategy to control the identity of DNA samples in genetic association studies.

Jürgen Brockmöller, Ingolf Meineke, Daniel Sehrt, 2010, Pharmacogenomics.

Simultaneous determination of 5-aminosalicylic acid and 5-acetylaminosalicylic acid by high-performance liquid chromatography.

E. Brendel, I. Meineke, M. Zschunke, 1987, Journal of chromatography.

Measurement of free and bound malondialdehyde in plasma by high-performance liquid chromatography as the 2,4-dinitrophenylhydrazine derivative.

I. Meineke, C. Gleiter, J. Pilz, 2000, Journal of chromatography. B, Biomedical sciences and applications.

Pharmacokinetics of pantoprazole following single intravenous and oral administration to healthy male subjects

I. Meineke, C. Mey, M. Pue, 2006, European Journal of Clinical Pharmacology.

Concentration-effect relationship of the positive chronotropic and hypokalaemic effects of fenoterol in healthy women of childbearing age

T. Bouillon, R. Port, U. Gundert-Remy, 1996, European Journal of Clinical Pharmacology.

Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol Pharmacokinetics and Pharmacodynamics

C. Meisel, J. Brockmöller, M. Tzvetkov, 2004, Clinical pharmacology and therapeutics.

Morphine-6-O-β-D-glucuronide but not morphine-3-O-β-D-glucuronide binds to μ-, δ- and κ- specific opioid binding sites in cerebral membranes

U. Gundert-Remy, I. Meineke, C. Desel, 1996, Naunyn-Schmiedeberg's Archives of Pharmacology.

Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol‐lowering activity of (−)‐3s,5r‐fluvastatin and (+)‐3r,5s‐fluvastatin in healthy volunteers

Christian Meisel, Steffen Bauer, Jürgen Brockmöller, 2003, Clinical pharmacology and therapeutics.

Impact of the CYP2D6 ultra‐rapid metabolizer genotype on CIS‐ and trans‐doxepin pharmacokinetics and serotonin concentration in platelets

J. Brockmöller, I. Roots, I. Meineke, 2005 .

Routine measurement of fluoxetine and norfluoxetine by high-performance liquid chromatography with ultraviolet detection in patients under concomitant treatment with tricyclic antidepressants.

U. Gundert-Remy, I. Meineke, K. Schreeb, 1998, Therapeutic drug monitoring.

Improved solid-phase extraction and HPLC measurement of torasemide and its important metabolites.

J. Brockmöller, I. Meineke, Sabine Engelhardt, 2006, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Pharmacokinetics and pharmacodynamics of candesartan after administration of its pro-drug candesartan cilexetil in patients with mild to moderate essential hypertension – a population analysis

U. Gundert-Remy, I. Meineke, H. Feltkamp, 1997, European Journal of Clinical Pharmacology.

Simulation of complex pharmacokinetic models in Microsoft EXCEL

Jürgen Brockmöller, Ingolf Meineke, J. Brockmöller, 2007, Comput. Methods Programs Biomed..

SK&F 86466, a novel alpha-adrenolytic drug: effects on heart rate, blood pressure, and neuroendocrine function in supine resting position and in response to postural and cold stimulation in normal humans.

I. Meineke, C. D. De Mey, D. Enterling, 1989, Journal of cardiovascular pharmacology.

Relative Impact of Genotype and Enzyme Induction on the Metabolic Capacity of CYP2C9 in Healthy Volunteers

J. Brockmöller, I. Roots, S. Vormfelde, 2009, Clinical pharmacology and therapeutics.

Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers

Wolfgang Rohde, Christian Meisel, Steffen Bauer, 2002, Clinical pharmacology and therapeutics.

Limited contribution of CYP3A5 to the hepatic 6β-hydroxylation of testosterone

J. Brockmöller, L. Wojnowski, I. Meineke, 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.

Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype

U. Fuhr, J. Brockmöller, A. Jetter, 2006, Clinical pharmacology and therapeutics.

Torsemide renal clearance and genetic variation in luminal and basolateral organic anion transporters.

J. Brockmöller, G. Burckhardt, P. Nürnberg, 2006, British journal of clinical pharmacology.

Influence of CYP2C9 and CYP2D6 Polymorphisms on the Pharmacokinetics of Nateglinide in Genotyped Healthy Volunteers

C. Meisel, J. Brockmöller, W. Rohde, 2004, Clinical pharmacokinetics.

An add-in implementation of the RESAMPLING syntax under Microsoft EXCEL

Ingolf Meineke, I. Meineke, 2000, Comput. Methods Programs Biomed..

Evaluation of the 13CO2 kinetics in humans after oral application of sodium bicarbonate as a model for breath testing

I. Meineke, C. Mey, F. Bauer, 1993, European journal of clinical investigation.

Modelling of non-linear pharmacokinetics in sheep after short-term infusion of cardiotoxic doses of imipramine.

G. Hellige, U. Gundert-Remy, I. Meineke, 1997, Pharmacology & toxicology.

A cell‐kinetic model of CD34+ cell mobilization and harvest: development of a predictive algorithm for CD34+ cell yield in PBPC collections

P. Höcker, I. Meineke, A. Humpe, 2000, Transfusion.

Morphine-6-O-beta-D-glucuronide but not morphine-3-O-beta-D-glucuronide binds to mu-, delta- and kappa- specific opioid binding sites in cerebral membranes.

U. Gundert-Remy, I. Meineke, C. Desel, 1996, Naunyn-Schmiedeberg's Archives of Pharmacology.

Amelogenin-based sex identification as a strategy to control the identity of DNA samples in genetic association studies.

J. Brockmöller, M. Tzvetkov, S. Vormfelde, 2010, Pharmacogenomics.

Carbonyl Reductase 1 Is a Predominant Doxorubicin Reductase in the Human Liver

K. Huse, J. Brockmöller, L. Wojnowski, 2008, Drug Metabolism and Disposition.

Prandial and diurnal effects on the absorption of orally administered enteric coated 5-aminosalicylic acid (5-ASA).

I. Meineke, C. D. De Mey, 1992, British journal of clinical pharmacology.

Impact of genetic polymorphisms in CYP2C8 and rosiglitazone intake on the urinary excretion of dihydroxyeicosatrienoic acids.

U. Fuhr, J. Brockmöller, I. Meineke, 2008, Pharmacogenomics.

Transdermal delivery of mepindolol and propranolol in normal man. 2nd communication: pharmacokinetic and neuro-endocrine aspects.

C. Rehbock, I. Meineke, C. D. De Mey, 1989, Arzneimittel-Forschung.

is a predominant doxorubicin reductase in the human liver

L. Wojnowski, I. Meineke, U. Zanger, 2008 .